EverGlade

EverGlade Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for patients with rare and orphan diseases, with a primary focus on dermatological conditions. The company's lead program, EG-101, is a proprietary topical formulation of a small molecule mTOR inhibitor currently in Phase 2 clinical development for the treatment of Pachyonychia Congenita (PC). PC is a rare genetic disorder that causes significant pain and disability due to thickened skin on the feet and nails, for which there are currently no FDA-approved treatments. EverGlade leverages its expertise in orphan drug development and a lean operational model to advance its pipeline efficiently. The company is led by industry veterans with a track record of successful drug development and commercialization in the specialty pharma space.